跳至主要内容
临床试验/NCT00326131
NCT00326131终止1 期

Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer

Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2006年4月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
发起方
入组人数
6
试验地点
1
主要终点
To assess the Pharmacokinetics, metabolism, and routes and extent of elimination of a single dose of [14C] BMS-275183 over a 10 day period.

研究概览

简要总结

The first purpose of this study is to determine how the body absorbs, metabolizes, and eliminates a single dose of BMS-275183 (labeled with radioactive carbon). Secondly, to measure the levels of BMS-275183 in your blood, study the safety of the drug, and to see what effects it has on your cancer.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Non-hematological malignancy that has progressed on standard therapy
  • No more that 3 prior chemotherapies given for advanced cancer
  • Adequate renal, hepatic and hematologic function

排除标准

  • Uncontrolled or significant pulmonary or cardiovascular disease
  • Active Brain metastases
  • Inability to swallow capsules
  • Serious uncontrolled medical disorder or active infection

结局指标

主要结局

To assess the Pharmacokinetics, metabolism, and routes and extent of elimination of a single dose of [14C] BMS-275183 over a 10 day period.

次要结局

  • To assess the safety of a single dose of [14C] BMS-275183 followed by a therapeutic regimen of BMS-275183 administered twice weekly

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验